Blazing Star Merger Sub completes Walgreens debt tender offer
RAANANA, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a micro-cap biotech firm with a market capitalization of $3.46 million focused on developing nasal hydrogels, has launched preclinical studies for an intranasal form of Naloxone, a drug used to counteract opioid overdoses. According to InvestingPro data, the company currently trades at $0.83 per share, with significant price volatility characterizing its recent market performance. The research is being conducted in collaboration with Professor Fabio Sonvico from the University of Parma, an expert in intranasal drug delivery.
The studies aim to evaluate the drug loading, release kinetics, nasal deposition, and stability of Naloxone when delivered through Polyrizon’s proprietary Trap and Target™ (T&T) platform. This platform is designed to enhance the bioavailability and effectiveness of medications administered nasally. According to Tomer Izraeli, CEO of Polyrizon, the T&T platform could potentially improve Naloxone administration by ensuring rapid opioid reversal in emergency situations.
The need for improved Naloxone delivery methods is underscored by the ongoing opioid epidemic, which has seen a significant rise in overdose deaths, particularly due to synthetic opioids like fentanyl. Naloxone is an FDA-approved opioid antagonist that can reverse the effects of opioid toxicity if administered quickly.
The global Naloxone market is expected to grow to $2.47 billion by 2032, with the intranasal spray segment projected to reach $1.4 billion by 2030. The intranasal route offers several advantages, including ease of use, no requirement for medical training, and a reduced risk of needlestick injuries, making it more accessible for emergency responders and individuals at risk.
Polyrizon’s development of intranasal hydrogels, including their Capture and Contain™ (C&C) technology, aims to provide a barrier against viruses and allergens in the nasal cavity. The company is further developing this technology for the intranasal delivery of active pharmaceutical ingredients (APIs).
This press release contains forward-looking statements regarding the potential benefits of the T&T platform for enhancing intranasal Naloxone. However, these statements are based on current expectations and projections and are subject to risks and uncertainties that could cause actual results to differ.
Information in this article is based on a press release statement and does not endorse any claims made by Polyrizon Ltd. For comprehensive financial analysis and additional insights, including eight more exclusive ProTips about PLRZ, visit InvestingPro. The platform reveals crucial metrics about the company’s financial health, which currently rates as ’Weak’ with an overall score of 1.74 out of 5.
In other recent news, Polyrizon Ltd. has filed a divisional patent application in Israel for its Trap & Target (T&T) platform technology. This development is part of the company’s efforts to enhance its intranasal drug delivery system, which aims to improve medication efficacy by increasing residence time and contact with mucosal tissues. The T&T technology is designed to enhance the bioavailability of active pharmaceutical ingredients, offering controlled release and preventing dripping from the nasal cavity. The technology is compatible with various drug types, including small molecules and antibodies, and utilizes biodegradable components. This patent filing complements Polyrizon’s recent U.S. patent application, which covers aspects of its two core technologies: Capture and Contain (C&C™) and T&T. The C&C platform aims to create a barrier against airborne threats like allergens and viruses by adhering to the nasal mucosa. Polyrizon’s ongoing patent efforts reflect its commitment to securing intellectual property and advancing technology to address healthcare challenges. The company specializes in developing medical device hydrogels in the form of nasal sprays designed to create a barrier against viruses and allergens.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.